Transcript: Manufacturing Depression: A Journey into the Economy of Melancholy

Alex: Welcome to another episode of ResearchPod. Today we're looking at an essay by Gary Greenberg that examines how modern clinical trials transform ordinary human distress into billable psychiatric disorders.

Sam: So this piece is tracking how everyday melancholy gets recoded as a medical diagnosis—and what that conversion actually costs?

Alex: That's the central puzzle. Greenberg follows himself into a Massachusetts General Hospital depression trial, and what he's really tracking is the machinery: how a structured interview systematically recodes a therapist's existential pessimism into a trial candidate.

Sam: How does that conversion actually work? Is there a biological assay involved, or does the whole thing rest on diagnostic inventories?

Alex: There is no laboratory test. The entire classification rests on standardized rating scales—the Hamilton Depression Rating Scale being the primary instrument. Think of it less like a blood test and more like an automated sorting machine: a rigid set of criteria strips away biographical context and funnels varied human complaints into a single diagnostic bin.

Sam: And the essay suggests the screening process itself is calibrated to push borderline cases across the threshold into major depressive disorder.

Alex: That's the core tension Greenberg identifies. The structured interview uses DSM criteria not as a neutral filter but as a mechanism that actively shapes who qualifies. Once classified, patients enter trials testing everything from blockbuster SSRIs to omega-3 supplementation. The diagnostic instrument doesn't just describe the population—it constitutes it.

Sam: So the entire enterprise rests on the assumption that complex emotional pain maps cleanly onto these checkboxes.

Alex: That's the baseline assumption of modern psychopharmacology, and Greenberg's account is really a sustained inquiry into what gets lost in that translation.

Sam: What's the actual intervention being tested in the trial he joins?

Alex: A three-armed design: two omega-3 fatty acid formulations—EPA and DHA—against placebo. The proposed mechanism is that these lipids render neuronal membranes more flexible, which is supposed to optimize whatever serotonin signaling is available. After two weeks, Greenberg reports no meaningful subjective shift from the supplements.

Sam: Which loops back to the wider problem with the serotonin hypothesis—that it's remained largely circumstantial after half a century of pharmacological intervention.

Alex: Right. SSRIs manipulate those pathways, but the underlying deficiency model has never been definitively established. The drugs work for some people, but the mechanism of action is still contested. What Greenberg is pointing at is the epistemological consequence of that gap: if the biological target is elusive, the questionnaire score effectively becomes the disease. The instrument isn't measuring something that exists independently of it—it's doing constitutive work.